Table 2:

Anti-inflammatory MSC EVs – Augmented Potency

Animal model	Type of Augmentation	Active molecule/stimuli	Route of administration	Citation
Colitis	Biochemical priming	TNFa, IFNg	IP	32
Liver fibrosis	Biochemical priming	IFNg	IV	33
Tendon injury	Biochemical priming	IFNg	Local biomaterial diffusion	34
Chronic asthma	Hypoxic preconditioning	Hypoxia	IV	37
Lung fibrosis	Physical	3D culture	Intranasal	38
Rheumatoid arthritis	Overexpression	miR-320a	IV	42
Autoimmune hepatitis	Overexpression	miR-223	IP	43
Myocardial infarction	Overexpression	miR-200b-3p	Intracardiac injection	44
Systemic inflammation	Genetic engineering	TNFR1, IL-6ST	IV	49